Showing results (851-860 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 18, 1998
Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitroC Etievant, J M Barret, A Kruczynski, et al.
Investigational New Drugs|September 18, 1998
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancyA I Einzig, P H Wiernik, S Wadler, et al.
Investigational New Drugs|September 18, 1998
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumorsN W Peacock, H A Burris, V Dieras, et al.
Investigational New Drugs|September 18, 1998
Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapyM J Edelman, D R Gandara, E A Perez, et al.
Investigational New Drugs|January 29, 2010
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancerBassel Fuad El-Rayes, Philip A Philip, Fazlul H Sarkar, et al.
Investigational New Drugs|April 25, 2022
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human studyPatricia LoRusso, Mark J Ratain, Toshihiko Doi, et al.
Investigational New Drugs|October 11, 2021
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancerAri Nishimura, Akira Ono, Kazushige Wakuda, et al.
Investigational New Drugs|January 1, 1986
Activity of flavone acetic acid (NSC-347512) against solid tumors of miceT H Corbett, M C Bissery, A Wozniak, et al.
Investigational New Drugs|January 1, 1986
Didemnin B. The first marine compound entering clinical trials as an antineoplastic agentH G Chun, B Davies, D Hoth, et al.
Investigational New Drugs|August 25, 2020
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, et al.
Pageof 372